Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Pralatrexate is a type of antifolate drug which means is restrains the production of folic
acid in the body. Folic acids are used by tumors to increase tumor cell growth and division.
It is believed that reducing folic acid will hinder the rapid division of tumor cells, their
growth and production. Carboplatin is an FDA approved chemotherapy drug for ovarian,
fallopian tube and primary peritoneal cancer. Some antifolate drugs are used with other
chemotherapy drugs to enhance cancer-fighting characteristics. It is believed that the study
drug pralatrexate may improve the anti-tumor effect of carboplatin. In this research study we
are looking for the highest dose of pralatrexate that can be given safely in combination with
carboplatin.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute National Comprehensive Cancer Network
Treatments:
Aminopterin Carboplatin Folic Acid Hydroxocobalamin Vitamin B 12